Exoderil External solution, 1%, 20 ml
Dosage:
1% x 20ml
1% x 30ml
Category
Antifungal
Scope of the drug
Leather
,
Dermatology
Release form
Solution
Manufacturer country
Austria
Package quantity, pcs
one
Exoderil solution for narcotics
approx.
1% fl.
20ml No. 1
Name ENG
EXODERIL
Clinical and pharmacological group
Antifungal drug for external use
ATX code
Naftifine
Dosage
1% x 20ml
Structure
1 ml of solution contains: active substance: naftifine hydrochloride - 10 mg
excipients: propylene glycol - 50 mg, ethanol - 400 mg, purified water - 475 mg.
Storage conditions and periods
At a temperature not higher than 30 degrees.
Expiration date: 5 years
after opening - 6 months
INN / Active ingredient
Naftifin
Specifications
Category
Antifungal
Scope of the drug
Leather
,
Dermatology
Release form
Solution
Manufacturer country
Austria
Package quantity, pcs
one
Scope of application
Dermatology
Way of introduction
Locally
,
Outwardly
Vacation conditions
Without recipe
Volume, ml.
20 ml
Brand name
Sandoz
The amount of the dosage form in the primary package
20 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antifungal agent
Anatomical and therapeutic characteristics
D01AE22 Naftifine
Dosage form
Solution for external use
Packaging
Box
The target audience
Adult
Dosage (volume) of the substance in the preparation
1 ml: naftifine hydrochloride 10 mg
Expiration date in days
1826
Package weight, g
fifty
Mode of application
:
Outwardly.
Exoderil is applied once a day to the affected skin surface and adjacent areas (approximately 1 cm of healthy skin along the edges of the affected area) after thorough cleaning and drying.
The duration of therapy for dermatomycosis is 2-4 weeks (if necessary - up to 8 weeks), with candidiasis - 4 weeks.
In case of nail damage, Exoderil is applied 2 times a day to the affected nail.
Before the first use of the drug, the affected part of the nail is removed as much as possible with scissors or a nail file.
The duration of therapy for onychomycosis is up to 6 months.
To prevent relapse, treatment should be continued for at least 2 weeks after the disappearance of clinical symptoms.